BRPI0517314A - derivados de indol e benzimidazol - Google Patents
derivados de indol e benzimidazolInfo
- Publication number
- BRPI0517314A BRPI0517314A BRPI0517314-0A BRPI0517314A BRPI0517314A BR PI0517314 A BRPI0517314 A BR PI0517314A BR PI0517314 A BRPI0517314 A BR PI0517314A BR PI0517314 A BRPI0517314 A BR PI0517314A
- Authority
- BR
- Brazil
- Prior art keywords
- indole
- compounds
- benzimidazole derivatives
- novel
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
DERIVADOS DE INDOL E BENZIMIDAZOL. A invenção atual relaciona-se aos compostos novos do indol e do benzimidazol e aos sais farmaceuticamente aceitáveis, aos ésteres ou à pró-drogas disso, às composições dos compostos novos junto com portadores farmaceuticamente aceitáveis, e aos usos dos compostos novos. Os compostos da invenção têm a seguinte fórmula geral (i).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62038504P | 2004-10-19 | 2004-10-19 | |
PCT/US2005/036803 WO2006049835A2 (en) | 2004-10-19 | 2005-10-14 | Indole and benzimidazole derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0517314A true BRPI0517314A (pt) | 2008-10-07 |
Family
ID=36123937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0517314-0A BRPI0517314A (pt) | 2004-10-19 | 2005-10-14 | derivados de indol e benzimidazol |
Country Status (11)
Country | Link |
---|---|
US (2) | US7608723B2 (pt) |
EP (2) | EP2275412A1 (pt) |
JP (1) | JP2008517057A (pt) |
KR (1) | KR20070072598A (pt) |
CN (1) | CN101233115A (pt) |
AU (1) | AU2005301133A1 (pt) |
BR (1) | BRPI0517314A (pt) |
CA (1) | CA2584979A1 (pt) |
MX (1) | MX2007004699A (pt) |
RU (1) | RU2007118523A (pt) |
WO (1) | WO2006049835A2 (pt) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2518224C (en) * | 2003-03-07 | 2010-06-15 | Astrazeneca Ab | Novel isothiazolopyrimidinones and isoxazolopyrimidinones and uses thereof |
EP1773830A1 (en) * | 2004-07-22 | 2007-04-18 | AstraZeneca AB | Fused pyrimidones useful in the treatment and the prevention of cancer |
KR20070046176A (ko) * | 2004-08-18 | 2007-05-02 | 아스트라제네카 아베 | 특정 융합 피리미돈의 거울상이성질체 및 이의 암 치료 및예방에 있어서의 용도 |
MX2007004699A (es) * | 2004-10-19 | 2007-06-14 | Novartis Vaccines & Diagnostic | Derivados de indol y bencimidazol. |
WO2006060737A2 (en) * | 2004-12-03 | 2006-06-08 | Takeda San Diego, Inc. | Mitotic kinesin inhibitors |
US8129358B2 (en) * | 2006-11-13 | 2012-03-06 | Novartis Ag | Substituted pyrazole and triazole compounds as KSP inhibitors |
KR20090097210A (ko) * | 2007-01-05 | 2009-09-15 | 노파르티스 아게 | 키네신 방추체 단백질 (eg-5) 억제제로서의 이미다졸 유도체 |
DE102007037579B4 (de) | 2007-08-09 | 2012-05-16 | Emc Microcollections Gmbh | Neue Benzimidazol-2-yl-alkylamine und ihre Anwendung als mikrobizide Wirkstoffe |
CN102186833A (zh) * | 2008-08-18 | 2011-09-14 | 耶鲁大学 | Mif调节剂 |
US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
PL2448938T3 (pl) | 2009-06-29 | 2014-11-28 | Incyte Holdings Corp | Pirymidynony jako inhibitory PI3K |
US8759359B2 (en) * | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
WO2011075630A1 (en) * | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors |
WO2011130342A1 (en) | 2010-04-14 | 2011-10-20 | Incyte Corporation | FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS |
CN103153970A (zh) * | 2010-04-15 | 2013-06-12 | 诺瓦提斯公司 | 作为ksp抑制剂的*唑和噻唑化合物 |
EA201201404A1 (ru) | 2010-04-15 | 2013-04-30 | Новартис Аг | Триазолы как ингибиторы кбв (кинезин-белок веретена) |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
JP5961187B2 (ja) | 2010-12-20 | 2016-08-02 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Pi3k阻害剤としてのn−(1−(置換フェニル)エチル)−9h−プリン−6−アミン |
US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
HUE030869T2 (en) | 2011-09-02 | 2017-06-28 | Incyte Holdings Corp | Heterocyclic amines as inhibitors of PI3K |
CN102627578B (zh) * | 2011-10-20 | 2014-06-11 | 南京大学 | 苯基苄胺类化合物及其应用 |
KR101939710B1 (ko) | 2011-12-21 | 2019-01-17 | 노비라 테라퓨틱스, 인코포레이티드 | B형 간염의 항바이러스성 제제 |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
CN102603544A (zh) * | 2012-04-06 | 2012-07-25 | 南京大学 | 一种抗炎化合物、其制备及其用途 |
KR20210081451A (ko) | 2012-08-28 | 2021-07-01 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도 |
WO2014131847A1 (en) | 2013-02-28 | 2014-09-04 | Janssen R&D Ireland | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
PT2981536T (pt) | 2013-04-03 | 2017-08-09 | Janssen Sciences Ireland Uc | Derivados de n-fenil-carboxamida e sua utilização como medicamentos para o tratamento da hepatite b |
JP6441315B2 (ja) | 2013-05-17 | 2018-12-19 | ヤンセン・サイエンシズ・アイルランド・ユーシー | スルファモイルチオフェンアミド誘導体およびb型肝炎を治療するための医薬品としてのその使用 |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
US9549988B2 (en) | 2013-06-09 | 2017-01-24 | RJS Biologics | Pharmaceutical compounds targeted by MIF affinity-tethered moieties |
WO2015011281A1 (en) | 2013-07-25 | 2015-01-29 | Janssen R&D Ireland | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
DK3060547T3 (en) | 2013-10-23 | 2018-01-15 | Janssen Sciences Ireland Uc | CARBOXAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATMENT OF HEPATITS B |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
CA2936947A1 (en) | 2014-02-05 | 2015-08-13 | Novira Therapeutics, Inc. | Combination therapy for treatment of hbv infections |
US11078193B2 (en) | 2014-02-06 | 2021-08-03 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
US10786578B2 (en) | 2014-08-05 | 2020-09-29 | Novartis Ag | CKIT antibody drug conjugates |
AU2016222556B2 (en) | 2015-02-27 | 2020-08-27 | Incyte Holdings Corporation | Salts of Pl3K inhibitor and processes for their preparation |
JP2018510159A (ja) | 2015-03-19 | 2018-04-12 | ノヴィラ・セラピューティクス・インコーポレイテッド | アゾカン及びアゾナン誘導体及びb型肝炎感染症の治療法 |
WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
JP6845231B2 (ja) | 2015-09-29 | 2021-03-17 | ノヴィラ・セラピューティクス・インコーポレイテッド | B型肝炎抗ウイルス薬の結晶形態 |
JP2019511542A (ja) | 2016-04-15 | 2019-04-25 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | カプシド集合阻害剤を含む組み合わせ及び方法 |
WO2018081361A1 (en) * | 2016-10-28 | 2018-05-03 | Children's Hospital Medical Center | Methods and compositions for treatment of myelodyspastic syndromes and/or acute myleoid leukemias |
AU2019235522A1 (en) | 2018-03-14 | 2020-09-03 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
US11096931B2 (en) | 2019-02-22 | 2021-08-24 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
AU2020269897A1 (en) | 2019-05-06 | 2021-10-14 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
WO2024099898A1 (en) * | 2022-11-07 | 2024-05-16 | Merck Patent Gmbh | Substituted bi-and tricyclic hset inhibitors |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
JPH03200961A (ja) * | 1989-10-03 | 1991-09-02 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
JPH04184433A (ja) * | 1990-11-20 | 1992-07-01 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
JPH04321046A (ja) * | 1991-02-15 | 1992-11-11 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料の処理方法 |
US5185450A (en) | 1991-02-19 | 1993-02-09 | University Of South Florida | Tetrazolium compounds for cell viability assays |
JP2847273B2 (ja) * | 1991-11-22 | 1999-01-13 | 富士写真フイルム株式会社 | カラー画像形成方法 |
JPH063775A (ja) * | 1992-06-22 | 1994-01-14 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
US6489300B1 (en) | 1997-07-31 | 2002-12-03 | Eugene D. Thorsett | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6271241B1 (en) | 1999-04-02 | 2001-08-07 | Neurogen Corporation | Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors |
JP2002541146A (ja) | 1999-04-02 | 2002-12-03 | ニューロゲン コーポレイション | アリールおよびヘテロアリール融合のアミノアルキル−イミダゾール誘導体および糖尿病薬としてのその使用 |
US6358949B1 (en) * | 1999-04-02 | 2002-03-19 | Neurogen Corporation | Aryl and hetroaryl fused aminoalkyl-imidazole derivatives: selective modulators of bradykinin B2 receptors |
US6545004B1 (en) | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
MXPA02004162A (es) | 1999-10-27 | 2003-08-20 | Cytokinetics Inc | Metodo y composiciones que utilizan quinazolinonas. |
IL154222A0 (en) | 2000-08-01 | 2003-07-31 | Sod Conseils Rech Applic | Imidazolyl derivatives |
AU2001296799A1 (en) | 2000-10-06 | 2002-04-15 | Neurogen Corporation | Benzimidazole and indole derivatives as crf receptor modulators |
JP2004515496A (ja) * | 2000-12-07 | 2004-05-27 | アストラゼネカ・アクチエボラーグ | ベンズイミダゾール治療剤 |
US20040132830A1 (en) | 2001-01-19 | 2004-07-08 | Finer Jeffrey T | Triphenylmethane kinesin inhibitors |
US6992082B2 (en) | 2001-01-19 | 2006-01-31 | Cytokinetics, Inc. | Phenothiazine kinesin inhibitors |
US7060705B2 (en) | 2001-11-07 | 2006-06-13 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
US6753428B2 (en) | 2001-11-20 | 2004-06-22 | Cytokinetics, Inc. | Process for the racemization of chiral quinazolinones |
EP1465896A4 (en) | 2001-12-06 | 2006-01-11 | Merck & Co Inc | MITOTIC INHIBITORS OF KINESIN |
US7262186B2 (en) | 2001-12-06 | 2007-08-28 | Merck & Co., Inc. | Substituted pyrazolo[3,4-d] pyrimidinones as a mitotic kinesin inhibitor |
WO2003049678A2 (en) | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
EP1481077B1 (en) | 2001-12-06 | 2009-11-04 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
JP4597519B2 (ja) | 2001-12-06 | 2010-12-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 有糸***キネシン阻害薬 |
WO2003060475A2 (en) * | 2002-01-10 | 2003-07-24 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues |
EP1465888A2 (en) | 2002-01-10 | 2004-10-13 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues |
AU2003213092A1 (en) | 2002-02-15 | 2003-09-09 | Smithkline Beecham Corporation | Syntheses of quinazolinones |
CA2478068C (en) | 2002-03-08 | 2011-02-08 | Merck & Co., Inc. | Dihydropyrazole compounds useful for treating or preventing cancer |
AU2003270015A1 (en) | 2002-05-09 | 2003-12-02 | Cytokinetics, Inc. | Compounds, compositions, and methods |
CA2485148A1 (en) | 2002-05-09 | 2003-11-20 | Cytokinetics, Inc. | Pyrimidinone compounds, compositions and methods |
US20040053948A1 (en) | 2002-05-10 | 2004-03-18 | Cytokinetics, Inc. | Compounds, compositions and methods |
CA2483627A1 (en) | 2002-05-23 | 2003-12-04 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
AU2003265242A1 (en) | 2002-05-23 | 2003-12-22 | Cytokinetics, Inc. | Compounds, compositions, and methods |
CA2486215A1 (en) | 2002-06-14 | 2003-12-24 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
AU2003245453B2 (en) | 2002-06-14 | 2008-08-14 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
EP1551962A4 (en) | 2002-07-08 | 2007-08-01 | Merck & Co Inc | MITOTIC KINESIN BINDING CENTER |
US6949538B2 (en) | 2002-07-17 | 2005-09-27 | Cytokinetics, Inc. | Compounds, compositions, and methods |
AU2003256805A1 (en) | 2002-07-23 | 2004-02-09 | Cytokinetics, Inc. | Compounds compositions and methods |
EP1539180A4 (en) | 2002-08-21 | 2006-08-30 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
WO2004024086A2 (en) | 2002-09-13 | 2004-03-25 | Cytokinetics, Inc. | Compounds, compositions and methods |
AU2003900608A0 (en) * | 2003-02-11 | 2003-02-27 | Fujisawa Pharmaceutical Co., Ltd. | Hdac inhibitor |
AU2004251175A1 (en) * | 2003-06-05 | 2005-01-06 | Merck & Co., Inc. | Substituted indoles and a process for preparing substituted indoles |
JP2007509082A (ja) * | 2003-10-22 | 2007-04-12 | アルピダ エー/エス | ペプチドデホルミラーゼ阻害剤としてのベンゾイミダゾール誘導体類およびそれらの使用 |
MX2007004699A (es) | 2004-10-19 | 2007-06-14 | Novartis Vaccines & Diagnostic | Derivados de indol y bencimidazol. |
-
2005
- 2005-10-14 MX MX2007004699A patent/MX2007004699A/es not_active Application Discontinuation
- 2005-10-14 US US11/251,440 patent/US7608723B2/en not_active Expired - Fee Related
- 2005-10-14 KR KR1020077011415A patent/KR20070072598A/ko not_active Application Discontinuation
- 2005-10-14 CN CNA2005800402742A patent/CN101233115A/zh active Pending
- 2005-10-14 RU RU2007118523/04A patent/RU2007118523A/ru not_active Application Discontinuation
- 2005-10-14 CA CA002584979A patent/CA2584979A1/en not_active Abandoned
- 2005-10-14 AU AU2005301133A patent/AU2005301133A1/en not_active Abandoned
- 2005-10-14 JP JP2007537929A patent/JP2008517057A/ja active Pending
- 2005-10-14 BR BRPI0517314-0A patent/BRPI0517314A/pt not_active IP Right Cessation
- 2005-10-14 EP EP10181182A patent/EP2275412A1/en not_active Withdrawn
- 2005-10-14 WO PCT/US2005/036803 patent/WO2006049835A2/en active Application Filing
- 2005-10-14 US US11/665,956 patent/US8008335B2/en not_active Expired - Fee Related
- 2005-10-14 EP EP05851219A patent/EP1807399A2/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
RU2007118523A (ru) | 2008-11-27 |
CA2584979A1 (en) | 2006-05-11 |
US20060084687A1 (en) | 2006-04-20 |
WO2006049835A3 (en) | 2007-11-22 |
KR20070072598A (ko) | 2007-07-04 |
EP2275412A1 (en) | 2011-01-19 |
WO2006049835A2 (en) | 2006-05-11 |
JP2008517057A (ja) | 2008-05-22 |
US8008335B2 (en) | 2011-08-30 |
US20080317744A1 (en) | 2008-12-25 |
US7608723B2 (en) | 2009-10-27 |
EP1807399A2 (en) | 2007-07-18 |
CN101233115A (zh) | 2008-07-30 |
AU2005301133A1 (en) | 2006-05-11 |
MX2007004699A (es) | 2007-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0517314A (pt) | derivados de indol e benzimidazol | |
BRPI0508230A (pt) | derivados de tiofeno substituìdo como agentes anti-cáncer | |
ATE404536T1 (de) | Substituierte chinolinderivate als inhibitoren von mitotischem kinesin | |
BR112014006283A2 (pt) | novos derivados de dihidroquinolina-2-ona | |
NI200700102A (es) | Derivados de indol tetraciclicos como agentes antiviricos | |
EA201200049A1 (ru) | 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17 | |
ATE517882T1 (de) | Chinolinderivate | |
CR11819A (es) | Compuestos de isoindolina 5-sustituidos | |
UY31940A (es) | Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones | |
ATE483707T1 (de) | 2-cyclopropylthiazolderivate | |
BRPI0414817A (pt) | derivados de ácido indol substituìdos e seu uso como inibidores de pai-l | |
BRPI0715579A2 (pt) | "composto, composição farmacêutica e uso de um composto" | |
EA201001724A1 (ru) | Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов | |
BRPI0806264A2 (pt) | derivados ciclizados como inibidores de eg-5 | |
EA200970341A1 (ru) | Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов | |
EA200700997A1 (ru) | 2,5- и 2,6-дизамещенные аналоги бензазола, полезные в качестве ингибиторов протеинкиназ | |
BR122018070508B8 (pt) | derivados de arilamida triazol-substituída e seu uso | |
ATE467632T1 (de) | Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors | |
ATE449776T1 (de) | Pyrroloä2,3-cüpyridinderivate | |
ATE399156T1 (de) | Neue indol- oder benzimidazol-derivate | |
ECSP088270A (es) | Derivados de (indol-3-il)-heterociclo como agonistas del receptor cannabinoide cb1 | |
ECSP099506A (es) | Derivados de 2-quinolinona y 2 quinoxalinona y su utilización como agentes anti bacterianos | |
EA201001882A1 (ru) | Гидроксизамещенные тиенопиримидиноны как антагонисты рецептора-i меланинконцентрирующего гормона | |
MA32834B1 (fr) | 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines | |
BRPI0516057A (pt) | derivados de indol como inibidores da ciclase de adenilato solúvel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |